NOT FOR DISTRIBUTION
Header cover image

Market Cap

€7.5b

Last Updated

2021/05/05 17:48 UTC

Data Sources

Company Financials +

Executive Summary

DiaSorin S.p.A. develops, manufactures, and distributes immunodiagnostics and molecular diagnostics tests for private and hospital microbiology laboratories worldwide. More Details

Rewards

PE ratio (31.2x) is below the Medical Equipment industry average (51.1x)

Earnings grew by 41.1% over the past year

Risk Analysis

No risks detected for DIA from our risk checks.


Snowflake Analysis

Flawless balance sheet with outstanding track record.


Similar Companies

Share Price & News

How has DiaSorin's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: DIA is not significantly more volatile than the rest of Italian stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: DIA's weekly volatility (5%) has been stable over the past year.


Market Performance


7 Day Return

-1.9%

DIA

1.0%

IT Medical Equipment

0.5%

IT Market


1 Year Return

-7.7%

DIA

26.8%

IT Medical Equipment

36.2%

IT Market

Return vs Industry: DIA underperformed the Italian Medical Equipment industry which returned 25.8% over the past year.

Return vs Market: DIA underperformed the Italian Market which returned 32.8% over the past year.


Shareholder returns

DIAIndustryMarket
7 Day-1.9%1.0%0.5%
30 Day1.0%5.1%0.3%
90 Day-19.9%2.5%8.7%
1 Year-7.1%-7.7%28.0%26.8%40.0%36.2%
3 Year84.7%75.6%70.1%63.8%4.8%-5.3%
5 Year190.7%169.7%158.2%138.5%25.3%1.3%

Long-Term Price Volatility Vs. Market

How volatile is DiaSorin's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is DiaSorin undervalued compared to its fair value and its price relative to the market?

31.19x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: DIA (€141.2) is trading above our estimate of fair value (€88.06)

Significantly Below Fair Value: DIA is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: DIA is good value based on its PE Ratio (31.2x) compared to the XE Medical Equipment industry average (51.1x).

PE vs Market: DIA is poor value based on its PE Ratio (31.2x) compared to the Italian market (21.7x).


Price to Earnings Growth Ratio

PEG Ratio: DIA is poor value based on its PEG Ratio (18.9x)


Price to Book Ratio

PB vs Industry: DIA is overvalued based on its PB Ratio (8.1x) compared to the XE Medical Equipment industry average (5.2x).


Future Growth

How is DiaSorin forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?

1.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: DIA's forecast earnings growth (1.6% per year) is below the savings rate (1.8%).

Earnings vs Market: DIA's earnings (1.6% per year) are forecast to grow slower than the Italian market (18.9% per year).

High Growth Earnings: DIA's earnings are forecast to grow, but not significantly.

Revenue vs Market: DIA's revenue (2.7% per year) is forecast to grow slower than the Italian market (2.8% per year).

High Growth Revenue: DIA's revenue (2.7% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: DIA's Return on Equity is forecast to be low in 3 years time (16.4%).


Past Performance

How has DiaSorin performed over the past 5 years?

15.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: DIA has high quality earnings.

Growing Profit Margin: DIA's current net profit margins (28.1%) are higher than last year (24.9%).


Past Earnings Growth Analysis

Earnings Trend: DIA's earnings have grown by 15.5% per year over the past 5 years.

Accelerating Growth: DIA's earnings growth over the past year (41.1%) exceeds its 5-year average (15.5% per year).

Earnings vs Industry: DIA earnings growth over the past year (41.1%) exceeded the Medical Equipment industry 5.3%.


Return on Equity

High ROE: DIA's Return on Equity (26%) is considered high.


Financial Health

How is DiaSorin's financial position?


Financial Position Analysis

Short Term Liabilities: DIA's short term assets (€713.9M) exceed its short term liabilities (€160.2M).

Long Term Liabilities: DIA's short term assets (€713.9M) exceed its long term liabilities (€129.9M).


Debt to Equity History and Analysis

Debt Level: DIA is debt free.

Reducing Debt: DIA currently has no debt however we can't compare to 5 years ago as we have no data for that period.

Debt Coverage: DIA has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: DIA has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is DiaSorin current dividend yield, its reliability and sustainability?

0.71%

Current Dividend Yield


Upcoming Dividend Payment

TodayMay 06 2021Ex Dividend DateMay 24 2021Dividend Pay DateMay 26 20212 days from Ex DividendBuy in the next 18 days to receive the upcoming dividend

Dividend Yield vs Market

Notable Dividend: DIA's dividend (0.71%) isn’t notable compared to the bottom 25% of dividend payers in the Italian market (1.33%).

High Dividend: DIA's dividend (0.71%) is low compared to the top 25% of dividend payers in the Italian market (3.91%).


Stability and Growth of Payments

Stable Dividend: DIA is not paying a notable dividend for the Italian market, therefore no need to check if payments are stable.

Growing Dividend: DIA is not paying a notable dividend for the Italian market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: DIA is not paying a notable dividend for the Italian market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of DIA's dividend in 3 years as they are not forecast to pay a notable one for the Italian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.0yrs

Average management tenure


CEO

Carlo Rosa (54 yo)

15.33yrs

Tenure

€1,330,000

Compensation

Mr. Carlo Rosa has been the Chief Executive Officer of DiaSorin S.p.A. since 2006 and has been its General Manager since April 27, 2010 also its Executive Director since March 26, 2007. In 2001, Mr. Rosa l...


CEO Compensation Analysis

Compensation vs Market: Insufficient data to establish whether Carlo's total compensation is reasonable compared to companies of similar size in the Italian market.

Compensation vs Earnings: Carlo's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: DIA's management team is seasoned and experienced (5 years average tenure).


Board Members

Experienced Board: DIA's board of directors are considered experienced (8.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

DiaSorin S.p.A.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: DiaSorin S.p.A.
  • Ticker: DIA
  • Exchange: BIT
  • Founded: 1968
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: €7.533b
  • Shares outstanding: 54.70m
  • Website: https://www.diasoringroup.com

Number of Employees


Location

  • DiaSorin S.p.A.
  • Via Crescentino
  • Saluggia
  • Vercelli
  • 13040
  • Italy

Listings


Biography

DiaSorin S.p.A. develops, manufactures, and distributes immunodiagnostics and molecular diagnostics tests for private and hospital microbiology laboratories worldwide. The company offers testing kits for i...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/05/05 17:48
End of Day Share Price2021/05/05 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.